Reference number(s) 1808-A

## SPECIALTY GUIDELINE MANAGEMENT

# **AUBAGIO** (teriflunomide)

## **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

<u>FDA-Approved Indication</u>: Aubagio is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

All other indications are considered experimental/investigational and are not covered benefits.

## II. CRITERIA FOR INITIAL APPROVAL


Authorization of 24 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis.

### **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

## IV. REFERENCE

1. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; November 2016.



© 2017 CVS Caremark. All rights reserved.

